9月9日 - ** Summit Therapeutics（SMMT.O）股价盘前上涨3.4%，至17.86美元
** 杰富瑞（Jefferies）将该股评级从“持有”上调至“买入”，并将目标价从15美元上调至25美元，此举基于该公司晚期肺癌临床试验将于2026年底公布的无进展生存期（PFS）数据
** 新目标价较该股上一交易日收盘价有44.7%的上行空间
** “我们认为，除非中国试验数据在扩展至全球试验时出现异常恶化，否则PFS很可能达到统计学显著性；且大多数情景都让我们对后续总生存期（OS）数据的积极结果充满信心”——杰富瑞
** 该券商表示，多项ivonescimab研究中积极的总生存期结果增强了其对该药物的信心，并强化了其PD-1/VEGF作用机制的有效性
** 杰富瑞表示，将中国研究结果推广至全球试验的风险似乎有限，并认为ivonescimab的“同类首创”地位将支撑其未来价值
** 18家券商中有12家给予该股“买入”或更高评级，6家给予“持有”评级；目标价中位数为32美元——LSEG数据
** 截至上一交易日收盘，该股年内累计下跌1.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.